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ABSTRACT 
BACKGROUND: The predictive value of short-term arm pain relief after ‘indirect’ 
cervical epidural steroid injection (ESI) for the 1-month treatment response has been 
previously demonstrated. It remained to be answered whether the long-term 
response could be estimated by the early post-interventional pain course as well. 
METHODS: Prospective observational study, following a cohort of n=45 patients for a 
period of 24 months after ‘indirect’ ESI for radiculopathy secondary to a single-level 
cervical disc herniation. Arm and neck pain on the visual analog scale (VAS), health-
related quality of life with the Short Form-12 (SF-12), and functional outcome with the 
Neck Pain and Disability (NPAD) Scale were assessed. Any additional invasive 
treatment after a single injection (second injection or surgery) defined treatment as 
‘non-response’. 
RESULTS: At 24 months, n=30 (66.7%) patients were responders and n=15 (33.3%) 
were non-responders. Non-responders exited the follow-up at 1 month (n=10), at 3 
months (n=4), and at 6 months (n=1). No patients were injected again, or operated 
on between the 6- and 24-month follow-up. Patients with favorable treatment 
response at 24 months had significantly lower VAS arm pain (p<0.05) than non-
responders at days 6, 8 – 11, and at the 3-month follow-up. The previously defined 
cut-off of >50% pain reduction was not a reliable predictor of the 24-month responder 
status. SF-12 and NPAD scores were better among treatment responders in the 
long-term. 
 
CONCLUSIONS: Patients who require a second injection or surgery after ‘indirect’ 
cervical ESI for a symptomatic CDH do so within the first 6 months. Short-term pain 
relief cannot reliably predict the long-term outcome. 
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Introduction 
The ‘indirect’ cervical epidural steroid injection (ESI) technique described by Sutter et 
al.[23] advocates a safe approach for treating radicular pain secondary to a cervical 
disc herniation (CDH). Our workgroup has previously shown how – as a rule of 
thumb – >50% arm pain relief within the first week after computed tomography (CT)-
guided ‘indirect’ cervical ESI could predict the 1-month treatment responder 
status.[13] In this follow-up study, we aimed to: 1) report long-term pain, health-
related quality of life (HRQoL) and functional outcome in the cohort of our previous 
series of patients undergoing ‘indirect’ cervical ESI for symptomatic CDH;[15] 2) 
verify whether the long-term responder status could be predicted by short-term arm 
pain relief; and 3) identify any other clinical or radiological predictors of treatment 
response. 
 
Methods 
Between August 2013 and March 2015, all patients between 18 – 70 years of age 
with cervical radicular pain, with or without additional findings of radiculopathy 
(numbness, paresthesias, muscle weakness and diminished reflexes), secondary to 
a single-level CDH, were prospectively screened for study inclusion at the 
Department of Radiology at Cantonal Hospital St. Gallen in Switzerland. All injections 
were performed by A.N., a radiologist with special interest and over 20 years of 
expertise in ESI,[1] who also reviewed all diagnoses and magnetic resonance 
imaging (MRI) findings from the referring physicians (general practitioners, pain 
physicians, rheumatologists, orthopaedic surgeons and neurosurgeons). 
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Electrophysiology was not routinely part of the diagnostic work-up. Patients with pre-
ESI arm pain <20/100 mm on the visual analog scale (VAS), red flags (severe motor 
deficit), myelopathy, multilevel disc herniation, concomittant stenosis, severe 
scoliosis, lack of symptom correlation with the imaging findings, previous ESI or 
surgery of the affected segment, uncorrectable bleeding diathesis, and a significant 
language barrier.[13] 
 
Baseline parameters 
Patient demographic data were collected before the injection. Profession according 
to the international standard classification of occupation,[12] work capacity in per 
cent, current use of opioids and symptom duration, as well as baseline intensity of 
arm and neck pain (VAS 0 to 100 mm), HRQoL (Short Form (SF)-12 questionnaire) 
and functional impairment (Neck Pain and Disability Scale[21] (NPAD)). As 
before,[13] CDH were classified as either preforaminal or foraminal based on MRI 
findings. 
 
Injection technique 
‘Indirect’ cervical ESI was performed according to Sutter et al.[23] under CT-
fluoroscopy guidance (Siemens SOMATOM Emotion®, Munich, Germany) as 
previously described.[13] A Terumo Agani® needle, 18-G, Short Bevel (Zhejiang 
Kindly Medical Devices Co., Ltd., Zhejiang, China; Shanghai International Holding 
Corp. GmbH (Europe), Hamburg, Germany) and Chiba needle (ECOJEKT 23-G, 15 
cm length, HS Hospital Service S.p.A., Aprilia, Italy) were used in coaxial technique 
to target the lateral aspect of the facet joint. Flashback/aspiration testing was 
performed and 0.3-0.5 ml saline-diluted iopamidol 300 mg/ml (Iopamiro 300®, Bracco 
Suisse SA, Manno, Switzerland) was applied and observed to spread around the 
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facet joint along the cervical root. Then, 4 mg dexamethasone (Mephameson®, 
Mepha Pharma AG, Basel, Switzerland) followed by 1 ml of 0.5% bupivacaine 
(Bupivacain Hydrochlorid®, Sintetica S.A., Mendrisio, Switzerland) were applied. 
After procedure, patients remained in the outpatient department for a minimum of 2 h 
for observation for any side effects. 
 
Outcome measurements, endpoints and definition of responder and non-responder 
status 
Patients received oral analgetics and physiotherapy as concomittant therapy that was 
not influenced by the study protocol. VAS arm and neck pain were recorded at the 
15, 30 and 45 minute (min; ultra-early), 1, 2 and 4 hour (h; early) time points, on days 
1-14 (d; intermediate), and at the 1-, 3-, 6-, as well as 12- and 24-month follow-up 
(long-term). At d14 as well as at each time point during the long-term follow-up, 
functional and HRQoL outcome, including opioid use, work capacity and satisfaction 
with ESI were assessed. When a study endpoint (second injection or surgery – 
anterior cervical decompression and fusion, or dorsal foraminotomy) was reached, 
the patient exited the follow-up and was considered non-responder. Responders had 
follow-up until 24 months after ESI. 
 
Statistical considerations 
Kaplan-Meier estimates response to treatment were graphically displayed. Log-rank 
tests were performed to analyze treatment failure distributions of two samples (time 
censored at 2 years). VAS arm and neck pain levels of responders and non-
responders in the ultra-early, early, intermediate and long-term follow-up were 
compared. Accounting for variations in pre-interventional VAS pain levels, relative 
pain at follow-up was displayed with the former set as 100% as handled before.[13] 
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Functional (NPAD) and HRQoL outcome (SF-12) were graphically illustrated as 
absolute values for better interpretability. 
Statistical between-group comparison for continous variables was performed using 
two-tailed unpaired t-tests. Chi-square tests were used to compare categorical 
variables. To be consistent with our previous report,[13] logistic regression was used 
to calculate the effect size of the relationship between >50% arm pain reduction at 
any given study visit, and the 24-month responder status; with results expressed as 
odds ratio and 95% confidence intervals. Since the study groups were well-balanced 
in important patient characteristics, no statistical adjustments were required. 
The software used for analysis was Stata v14.2 (StataCorp LP, College Station, 
Texas, USA). GraphPad Prism v5.0c (GraphPad Software, Inc. San Diego, 
California, USA) was used for drawing Figure 2. Probability-values of <0.1 (+) were 
considered a tendency, p-values of <0.05 (*) or <0.005 (**) were considered 
significant. 
 
Ethical considerations and data management 
Written informed consent was obtained from all included patients. The study was 
conducted in accordance with the ethical standards of the Cantonal Ethical Review 
Board St. Gallen, Switzerland (EKSG 13/061) with the Helsinki Declaration (1964, 
amended most recently in 2008) of the World Medical Association and registered 
under clinicaltrials.gov (Identifier: NCT01945554). 
All data were collected by a full-time study nurse (C.L.). In order to conceal patients’ 
identity, each study participant was given a unique patient number for follow-up 
questionnaires and data management.  
 
Results 
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Out of 231 screened patients who underwent cervical ESI during the study period, 53 
(22.9%) patients were found eligible for study inclusion. After the exclusion of eight 
patients (patient refusal for further participation; incomplete follow-up data), a total of 
45 patients were available for final analysis. At the 24-month follow-up, 30 patients 
(66.7%) were considered responders and 15 (33.3%) non-responders. Non-
responders exited the follow-up within 14 days (n=4; 2 second injection, 2 surgery); at 
1 month (n=6; 1 second injection, 5 surgery), at 3 months (n=4; 4 second injection), 
at 6 months (n=1; 1 surgery). No patients were injected again or operated on 
between the 6- and 24-month follow-up (Figure 1). 
 
Patient baseline data and procedure-related characteristics were well balanced 
between the two study groups with the exception of SF-12 physical component 
summary (Table 1). Two minor complications (4.4%; one transient episode of 
dizziness and one vasovagal syncope) were observed in the context of ESI. 
 
Long-term arm and neck pain, functional and HRQoL outcome 
Patients defined as responders were characterized by virtue of their significantly 
lower pain, functional, and HRQoL metrics, as well as reduced opioid use, better 
employment status and satisfaction with the treatment at 24 months, as compared to 
their counterparts (Table 2). 
Figure 2 displays the different courses of VAS arm and neck pain of responders and 
non-responders over time. A significant drop in relative pain occurred within the first 
hours after ESI in all patients. Over the following days, an increase to about 40% of 
the pre-ESI pain level was observed in those considered responders at 24 months. 
Non-responders had significantly higher pain recurrence. While there were no 
significant between-group differences in terms of VAS arm pain in the ultra-early and 
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early follow-up, 24-months responders could be differentiated from non-responders in 
the intermediate interval, as indicated in the figure. 
 
Effect size of the relationship >50% VAS arm pain relief and 24-month responder 
status 
Table 3 illustrates the effect size of the relationship between >50% VAS arm pain 
relief at each time point and the 24-month responder status. In the intermediate 
period, at days 6 and 10 after ESI, patients experiencing >50% pain relief were 5.14 
(95% CI 1.29 – 20.52) and 4.37 (95% CI 1.07 – 17.8) times as likely to be 24-months 
responders (Table 3). 
 
Radiological predictors of treatment success 
There was a non-significant trend for a higher rate of foraminal than preforaminal 
CDH in non-responders (Table 1). When stratifying the cohort by location, those with 
a CDH located in the foramen reached their study endpoints earlier as compared to 
patients with preforaminal CDH (Figure 3; log-rank p=0.116). 
 
Discussion 
Two-thirds of a prospective cohort of patients with symptomatic radicular pain 
secondary to a single-level CDH undergoing CT-guided ‘indirect’ cervical ESI did not 
require any extra procedures until the 24-month follow-up. Treatment failures 
became obvious within the first 6 months after the index procedure, and none of 
those considered responders required a second injection or surgery. Parallels can be 
drawn to a different prospective cohort of 57 patients who underwent transforaminal 
epidural injections for sciatica secondary to a lumbar disc herniation in which nearly 
all patients beyond the 6-month follow-up did not require additional invasive 
9"
treatment.[14, 15] Most likely, the favorable natural clinical long-term course of CDH 
with spontaneous regressions may obviate future treatment in many cases.[2] 
Another explanation for early re-treatment – as early as the first two weeks after the 
index procedure in our study cohort – may be cultural grounds, as patients from 
Switzerland seem to utilize their healthcare system on a lower threshold by 
requesting additional treatments with a short wait time.[14, 15] 
 
Only a few studies have previously addressed outcome prediction of short-term 
cervical radicular pain relief following ESI. A positive correlation between the 
reduction in numeric rating scale cervical radicular pain 15 min after ESI for 
osteophyte-related radicular impingement with pain reduction in the first three months 
was established by Desai et al.[6] In another cohort of 21 patients with mixed 
diagnoses of cervical disc herniation and spondylosis awaiting surgery, five patients 
cancelled after receiving two ESI treatments; the authors noted that the long-lasting 
treatment effect was instantaneous.[17] On the other hand, Wald et al.[25] found the 
2-month predictability of the 2-week numeric rating scale pain superior to the pain 
relief immediately after ESI. The 2-week interval post-ESI seems to be the most 
crucial, as in another study,[24] no further improvement beyond the 2-week follow-up 
was observed in those patients who had not responded by then. The aforementioned 
studies harbor significant methodological heterogeneities in terms of case mix[7, 17, 
24, 25], multi-level[7, 24]" and repeated injections[17, 24], omittance of local 
anesthetic[17, 24] and image guidance (fluoroscopy[17, 24] vs. CT[7, 25]). None of 
these studies followed their patients closely in order to work out a detailed course of 
treatment response. 
Hence, in 2013, we started a prospective trial-registered (clinicaltrials.gov identifier 
NCT01945554) clinical observation study with predefined strict inclusion criteria on 
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clinical and radiological grounds, and validated assessment tools. As a main finding, 
predicting the 1-month treatment response was most successful in patients who 
experienced a >50% pain relief within the first week after ESI for lumbar disc 
herniations,[15] as well as for CDH,[13] which may aid physicians in managing these 
patients in the short-term. In the current long-term follow-up report, the previously 
established relationship between >50% pain reduction during any given time point 
and the 24-month responder status was weak and only statistically significant on d6 
and d10 (Table 3). In conjunction with the recently published long-term results from 
our lumbar disc herniation cohort,[14] we have come to the conclusion that the value 
of short-term pain relief for the prediction of long-term outcome after ESI is low. 
Early exits of patients who reached their endpoint (=treatment failures) limited the 
size of the follow-up cohort. As we acknowledged beforehand,[14] our study design 
did not include assessments of patients’ pain levels, functional and HRQoL just 
before salvage treatment (second injection or surgery), which could have potentially 
strengthened the discriminative power of the graphs. Radiculopathy secondary to 
disc herniation has a heterogeneous and dynamic natural course of disease. For 
example, later re-current slippage of intervertebral disc material might prompt 
patients to opt for additional invasive treatment even if they had responded well to 
ESI in the beginning. Thus, the 50%-rule for predicting the 1-month outcome[13, 15] 
still holds true, but is complimented by the follow-up results of our current and recent 
publication[14] that underscore the uncertainties for the long-term predictability. 
Finding other clinical and radiological outcome predictors is warranted. Some 
authors[18-20] found pre-ESI pain duration to be a significant clinical predictor, while 
others could not establish a statistically significant effect.[5] A previous episode of 
cervical radiculopathy[20] and previous surgery[19] adversely affected outcome. 
Other than a lower SF-12 physical component summary in the non-responders, no 
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differences in baseline patient characteristics such as gender, body mass index, 
profession and employment status, or opioid use were noted in the current study, 
especially no difference in pain duration (Table 1). 
Whether the etiology determines cervical ESI outcome is still a matter of debate. 
While some authors[17, 20, 22] found no difference in outcome with so-called “hard” 
(spondylosis) and “soft” (disc herniation) compression, others[8, 20] reported cervical 
ESI to be more effective in the setting of cervical spondylosis than disc herniation 
and vice versa.[18] We eliminated any possible bias arising from the preoperative 
diagnosis by excluding patients with cervical spondylosis and foraminal stenosis. 
A few studies[16, 20, 22] looked into radiological predictors in greater detail. Strobel 
et al.[22] found a significant better response after cervical transforaminal ESI for 
foraminal (mean pain reductions of 64%; n=12) than for median or medio-lateral 
locations (41%; n=40). Radiological grading of nerve root compression did not result 
in statistically significant differences in pain relief.[22] Lee et al.[20] followed a cohort 
of 98 patients considered surgical candidates for cervical radiculopathy, who 
underwent ESI. There was no statistically significant difference in terms of location 
and extent of compression in patients, who later received surgery as compared to 
those who did not.[20] Likewise, Klessinger et al.[16] in their practice audit on 
patients after ESI found no statistically significant difference in treatment response 
with regard to the location or compression grade – a modification based on the 
system proposed by Ghahreman et al.[11] While the authors regard MRI as the gold 
standard technique for imaging work-up of cervical radicular pain, they critically 
emphasize that the inter-rater agreement between three blinded observers on the 
grading of nerve compression was poor with a Fleiss’ kappa = 0.1.[16] 
The missing statistically significant association of radiological parameters with ESI 
outcome in the present report (as well as previously, for the 1-month outcome[13]), in 
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conjunction with the aforementioned conflicting or negative results, paints a picture of 
very limited predictive value of radiological features, if at all. Despite the promising 
report by Ghahreman et al.,[11] the usefulness of radiological predictors for lumbar 
ESI could not be reproduced by subsequent studies.[14, 15] The limitations of 
radiological grading scales to correlate with a patient’s disability[4] or outcome[10] 
are well-known. Therefore, in the absence of red flags (severe/progressive motor 
deficit and cauda equina) requiring surgery, patient management with ESI up to now 
still mainly relies on individual experience, intuition and patient’s preference and 
should take into account age, labor status, co-morbidities, and disease-specific 
factors. 
 
Strengths and weaknesses 
We previously discussed the strengths and weaknesses of the study design.[13] 
Some considerations for limitations include potential concomitant treatment 
confounders (non-standardized analgetics, physiotherapy), strict exclusion criteria 
that limit generalizability to other populations and a preferably larger sample size. 
Contrary to our previous publication,[13] VAS arm pain >80% was not considered a 
study endpoint in the current follow-up study because of the potentially inflicting long-
term recall bias of the pre-ESI baseline pain at the 24-month follow-up.[13] Group 
differences between responders and non-responders were substantial and met the 
criteria for the commonly accepted minimum clinically important difference,[3, 9] 
which shows that the definition of the responder status was adequate. 
 
Conclusions 
Two-thirds of patients with radiculopathy secondary to a CDH will be long-term 
responders up to 24-months after ‘indirect’ cervical ESI. Most treatment failures 
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become evident within 6 months of the index procedure. The predictive value of 
short-term pain relief for the long-term responder status is unreliable, as are 
commonly recorded clinical and radiological variables. 
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FIGURE CAPTIONS 
 
Figure 1: Kaplan-Meier curve illustrating treatment failure (defined as a second 
injection or surgery) after ‘indirect’ cervical epidural steroid injection (ESI) for 
radicular pain secondary to a cervical disc herniation over time. Y-axis: Rate of study 
participants. X-axis: Time in days after ESI. Note that no additional patients failed 
treatment between the 6- and 24-month follow-up. 
 
Figure 2: Change in visual analog scale (VAS) arm (A) and neck pain (B) over time 
is illustrated for 30 and 15 patients who were considered responders and 
nonresponders at 24 months after ‘indirect’ cervical epidural steroid injection (ESI), 
respectively. X-axis Time after ESI in min, h, days and months. Y-axis Change in 
VAS pain (in %). + = p<0.1; * = p<0.05. Pain intensity is displayed in % (group means 
and standard errors), with pain intensity before ESI set at 100%. 
 
Figure 3: Kaplan-Meier curve illustrating treatment failure (defined as a second 
injection or surgery) after ‘indirect’ cervical epidural steroid injection (ESI) for 
radicular pain secondary to a cervical disc herniation over time, stratified for patients 
with preforaminal and foraminal location of nerve root compression. Y-axis Rate of 
study participants. X-axis Time in days after ESI. 
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 Responder Non-responder p-value 
Age in years 49.9 ± 9.4 51.3 ± 9.7 0.64 
Gender 
     Male 
     Female 
 
18 
12 
 
60.0% 
40.0% 
 
9 
6 
 
60.0% 
40.0% 
>0.99 
Body metrics 
     Height (cm) 
     Weight (kg) 
     BMI, (kg/m2) 
 
172.4 ± 11.1 
76.6 ± 15.3 
25.6 ± 3.3 
 
170.0 ± 7.5 
79.5 ± 26.5 
27.6 ± 9.8 
 
0.46 
0.65 
0.31 
Professional life 
      Pension 
      Jobless 
      Home keeper 
      Working 
 
2 
- 
2 
26 
 
6.7% 
0.0% 
6.7% 
86.6% 
 
2 
1 
- 
12 
 
13.3% 
6.7% 
0.0% 
80.0% 
0.39 
Occupation (%) 71.5 ± 38.9 71.8 ± 42.1 0.98 
ISCO group 
      1 Managers 
      2 Professionals 
      3 Technicians 
      4 Clerical support 
      5 Service/sale workers 
      6 Skilled workers 
      7 Craft/trade workers 
      8 Plant/machine operator 
      9 Elementary occupations 
 
- 
7 
1 
2 
9 
- 
4 
2 
2 
 
0.0% 
25.9% 
3.7% 
7.4% 
33.3% 
0.0% 
14.8% 
7.4% 
7.4% 
 
- 
5 
- 
1 
2 
- 
2 
1 
1 
 
0.0% 
41.7% 
0.0% 
8.3% 
16.7% 
0.0% 
16.7% 
8.3% 
8.3% 
0.95 
Location of herniated disc 
   Preforaminal 
   Foraminal 
 
18 
12 
 
60.0% 
40.0% 
 
5 
10 
 
33.3% 
66.7% 
0.12 
Cervical nerve root affected 
   C6 
   C7 
   C8 
 
16 
12 
2 
 
53.3% 
40.0% 
6.7% 
 
5 
10 
- 
 
33.3% 
66.7% 
0.0% 
0.24 
Side 
   Right 
   Left 
 
17 
13 
 
56.7% 
43.3% 
 
6 
9 
 
40.0% 
60.0% 
0.29 
Dose-length product (mGy*cm) 352.1 ± 123.5 358.2 ± 175.7 0.93 
Complications 
   Yes 
   No 
 
1* 
29 
 
3.3% 
96.7% 
 
- 
15 
 
0.0% 
100% 
>0.99 
Opioid use 
     Yes 
     No 
 
10 
20 
 
33.3% 
66.7% 
 
7 
8 
 
46.7% 
53.3% 
0.38 
Delay pain onset to injection (days) 159.0 ± 273.1 92.7 ± 144.4 0.39 
Pain, functional disability and HRQoL 
      VAS arm 
      VAS neck 
      NPAD total 
         NPAD pain 
         NPAD disability 
         NPAD function 
      SF-12 PCS 
      SF-12 MCS 
 
54.1 ± 16.1 
46.5 ± 23.3 
49.1 ± 16.2 
16.1 ± 5.0 
19.2 ± 8.1 
8.6 ± 4.6 
39.1 ± 8.6 
41.7 ± 10.1 
 
63.7 ± 21.5 
50.9 ± 28.8 
59.7 ± 18.2 
18.9 ± 4.9 
23.9 ± 8.9 
10.1 ± 5.2 
33.9 ± 5.2 
42.8 ± 8.2 
 
0.10 
0.58 
0.05 
0.08 
0.08 
0.35 
0.04 
0.73 
 n=30 (100%) n=15 (100%)  
 Table 1: Baseline and procedure-related characteristics of 30 and 15 patients considered 
responders and non-responders at 24 months after ‘Indirect’ cervical epidural steroid 
injections. Variables on an interval scale are presented as means with standard deviations 
(SD), and categorical variables as group counts and percent. Note that responders had 
slightly lower disease severity, as indicated by lower NPAD and higher SF-12 PCS values at 
baseline. 
BMI, body mass index; ISCO, International Standard Classification of Occupations; HRQoL 
health-related quality of life, VAS visual analog scale, NPAD Neck Pain and Disability Index, 
MCS Mental Component Summary, PCS Physical Component Summary, SF-12 Short Form-
12. 
Outcome Responder Non-responder p-value 
Pain 
      VAS arm 
      VAS neck 
 
11.2 ± 12.4 
15.0 ± 14.9 
 
49.3 ± 30.9 
41.2 ± 30.3 
 
<0.001 
<0.001 
Functional disability 
      NPAD total 
             NPAD pain 
             NPAD disability 
             NPAD function 
 
11.0 ± 14.0 
4.3 ± 5.9 
3.9 ± 5.9 
2.8 ± 3.6 
 
48.8 ± 27.1 
15.6 ± 8.2 
18.7 ± 11.9 
9.3 ± 5.5 
 
<0.001 
<0.001 
<0.001 
<0.001 
HRQoL 
      SF-12 PCS 
      SF-12 MCS 
 
49.4 ± 6.3 
48.4 ± 9.3 
 
33.1 ± 7.6 
41.4 ± 7.8 
 
<0.001 
0.019 
Regular use of opioids 
     Yes 
     No 
 
1 
29 
 
3.3% 
96.7% 
 
7 
8 
 
46.7% 
53.3% 
<0.001 
Occupation in % 90.7 ± 21.4% 58.2 ± 44.5% 0.004 
Survey 
      Yes 
             Certainly yes 
             Probably yes 
      No 
             Unsure 
             Probably not 
             Certainly not 
 
22 
15 
7 
8 
3 
3 
2 
 
73.3% 
 
 
26.7% 
 
 
4 
4 
- 
11 
2 
5 
4 
 
26.7% 
 
 
73.3% 
 
0.004 
 n=30 (100%) n=15 (100%)  
 
Table 2: Outcome of 30 and 15 patients considered responders (at 24 months) and non-
responders (at last follow-up before exiting the study) after ‘indirect’ cervical epidural steroid 
injection. Nominal variables are presented as means with standard deviations (SD) and 
categorical variables as group counts and percent. NPAD neck pain disability index, PCS 
Physical component summary, Survey Patients were asked whether they would choose to 
have an injection again, provided they had the same outcome, VAS Visual analog scale. 



